Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
RTOG Foundation, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02192359CT.gov Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | — | Active Not Recruiting | — | — | — |
NCT02386826CT.gov INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | — | Completed | — | — | — |
NCT02052648CT.gov Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | — | Completed | — | — | — |
NCT01837862CT.gov A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | — | Completed | — | — | — |
NCT01814813CT.gov Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT01648348CT.gov Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
NCT01609790CT.gov Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | — | Completed | — | — | — |
NCT01378481CT.gov High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | — | Terminated | — | — | — |
NCT01498328CT.gov A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | — | Completed | — | — | — |
NCT01339039CT.gov Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | — | Terminated | — | — | — |
Show 14 more trialsShow fewer
NCT01189240CT.gov RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | — | Terminated | — | — | — |
NCT00979017CT.gov Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00879437CT.gov Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma | — | Completed | — | — | — |
NCT00731731CT.gov Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00735436CT.gov A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | — | Terminated | — | — | — |
NCT00734682CT.gov A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | — | Completed | — | — | — |
NCT00641706CT.gov Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00667394CT.gov Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | — | Completed | — | — | — |
NCT00525525CT.gov Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | — | Completed | — | — | — |
NCT00597402CT.gov Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | — | Completed | — | — | — |
NCT00268385CT.gov Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | — | Active Not Recruiting | — | — | — |
NCT00238303CT.gov Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00612638CT.gov Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas | — | Completed | — | — | — |
NCT02055196CT.gov Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gliosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | RTOG Foundation, Inc. | P3 | BB · 68 |
| Cediranib | Northwestern University | P2 | BBB |
| Temsirolimus | National Cancer Institute (NCI) | P2 | BBB |
| Gefitinib | National Cancer Institute (NCI) | P2 | BB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BB |
| Sorafenib | University Hospital, Geneva | P2 | BB |
| Tandutinib | National Cancer Institute (NCI) | P2 | BB |
| Vorinostat | National Cancer Institute (NCI) | P2 | BB |
| Cyclophosphamide | Mayo Clinic | P2 | BB |
+42 more in the Gliosarcoma cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CediranibNorthwestern UniversityBBB
- TemsirolimusNational Cancer Institute (NCI)BBB
- GefitinibNational Cancer Institute (NCI)BB
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)BB
- SorafenibUniversity Hospital, GenevaBB
Citation
Floatz Terminal. Irinotecan in Gliosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-gliosarcoma-62201
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →